HTT

Chr 4

huntingtin

Also known as: HD, IT15, LOMARS

Huntingtin is a disease gene linked to Huntington's disease, a neurodegenerative disorder characterized by loss of striatal neurons. This is thought to be caused by an expanded, unstable trinucleotide repeat in the huntingtin gene, which translates as a polyglutamine repeat in the protein product. A fairly broad range of trinucleotide repeats (9-35) has been identified in normal controls, and repeat numbers in excess of 40 have been described as pathological. The huntingtin locus is large, spanning 180 kb and consisting of 67 exons. The huntingtin gene is widely expressed and is required for normal development. It is expressed as 2 alternatively polyadenylated forms displaying different relative abundance in various fetal and adult tissues. The larger transcript is approximately 13.7 kb and is expressed predominantly in adult and fetal brain whereas the smaller transcript of approximately 10.3 kb is more widely expressed. The genetic defect leading to Huntington's disease may not necessarily eliminate transcription, but may confer a new property on the mRNA or alter the function of the protein. One candidate is the huntingtin-associated protein-1, highly expressed in brain, which has increased affinity for huntingtin protein with expanded polyglutamine repeats. This gene contains an upstream open reading frame in the 5' UTR that inhibits expression of the huntingtin gene product through translational repression. [provided by RefSeq, Jul 2016]

GeneReviewsResearchGenerating clinical summary…

Clinical highlights

Gene-disease validity (ClinGen)
Huntington disease · ADDefinitivesufficient evidence for diagnostic panels
Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
12
Active trials
431
Pubs (1 yr)
P/LP submissions
P/LP missense
0.18
LOEUF· LoF intol.
Multiple*
Mechanism· predicted
📖
GeneReview available — HTT
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

  • tominersen
    ASOPhase 2

    Lowers total huntingtin.

    Delivery: Intrathecal

    Earlier phase 3 paused; dose/population re-evaluation ongoing

  • AMT-130
    AAV gene therapyPhase 1/2

    One-time delivery of a microRNA lowering (mutant) huntingtin.

    Delivery: Stereotactic intrastriatal

Therapeutic landscape as of 2026-07. Educational only. Investigational ≠ available; not medical advice or eligibility. Approved entries are precise; investigational program names/phases are conservative and move fast. Curated from FDA/EMA approvals and the clinical-trial literature; verify against current labeling + ClinicalTrials.gov.

ClinicalTrials.gov

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.18LOEUF
pLI 1.000
Z-score 10.27
OE 0.12 (0.080.18)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
2.78Z-score
OE missense 0.81 (0.780.85)
1404 obs / 1729.3 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?
LoF OE?0.12 (0.080.18)
00.351.4
Missense OE?0.81 (0.780.85)
00.61.4
Synonymous OE?1.10
01.21.6
LoF obs/exp: 19 / 158.6Missense obs/exp: 1404 / 1729.3Syn Z: -2.04

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

HTT · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Huntington Disease

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

RECRUITING
NCT07326709Phase PHASE3Novartis PharmaceuticalsStarted 2026-03-24
Votoplam (blinded)Placebo
Huntington Disease

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

RECRUITING
NCT05509153Phase PHASE2Western Sydney Local Health DistrictStarted 2024-06-01
NACPlacebo
Postnatal Depression

Home-based Transcranial Direct Current Stimulation in Postpartum Depression: the Feasibility Study and Pilot Study

NOT YET RECRUITING
NCT05046405Phase NAAna Ganho ÁvilaStarted 2022-10-02
Transcranial Direct Current Stimulation
Huntington Disease

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

ACTIVE NOT RECRUITING
NCT05541627Phase PHASE1, PHASE2AskBio France, SAS, a subsidiary of AskBio Inc.Started 2022-10-12
AB-1001 Gene Therapy
Parkinson DiseaseNervous System DisorderNeurodegenerative Diseases

Molecular and Functional Imaging in Monogenic PD.

RECRUITING
NCT05518617University of ExeterStarted 2022-07-01
Positron Emission Tomography (PET) scan using DASB tracer
Huntington's Disease (HD)

Biology-Driven Cognitive Profiling in Huntington's Disease

ACTIVE NOT RECRUITING
NCT07503743Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauStarted 2021-09-01
Huntington's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

ACTIVE NOT RECRUITING
NCT07246941Phase PHASE1Hoffmann-La RocheStarted 2025-11-19
RG6496Placebo
Preterm BirthMother-Infant InteractionInfant Development

Continuous Delivery Room Skin-to-skin-study for Moderate and Late Preterm Infants

RECRUITING
NCT05975203Phase NAUniversity of CologneStarted 2023-08-04
skin-to-skin contact
Huntington Disease

Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

RECRUITING
NCT04012411Phase NAUniversity Hospital, MontpellierStarted 2020-03-03
Brain MRILumbar PunctionBlood sample
Premature Ejaculation

Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy

NOT YET RECRUITING
NCT07057011Phase NASouth Valley UniversityStarted 2025-07-01
Paroxetine 20 Mg Oral Tablet
Huntington's Disease

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

ACTIVE NOT RECRUITING
NCT04120493Phase PHASE1, PHASE2UniQure Biopharma B.V.Started 2019-09-06
intra-striatal rAAV5-miHTTImitation (sham) surgery
Depression

Intern Health Study

ENROLLING BY INVITATION
NCT01809080University of MichiganStarted 2007-05